Keywords
Zika, Persistence, transmission, tissue reservoirs, drug and vaccine development
This article is included in the Emerging Diseases and Outbreaks gateway.
Zika, Persistence, transmission, tissue reservoirs, drug and vaccine development
After the recent outbreak of Zika virus (ZIKV) infection in Brazil and other countries, multiple studies have been published regarding various tissue reservoirs, including the eyes, nervous system, genitourinary tracts and placenta (Table 1). A recent report of ZIKV transmission in renal and liver transplant patients with abnormal graft functions1 poses a new challenge in screening organs intended for transplants and monitoring transplanted patients. Considering such new concerns for ZIKV, we have reviewed the existing literature about ZIKV tissue reservoirs in this article and provide our analysis of the potential impact of ZIKV reservoirs on transmission and challenges in development of medical countermeasures against ZIKV.
The role of immune-privileged sites (e.g. eyes, testes, fetal brain, and placenta) in harboring ZIKV has been previously reported2, contributing to the viral persistence in these tissues. Successful infection and amplification of ZIKV in vitro in primary cell cultures derived from the placenta3, kidney4, nervous tissue5, and amplification found in the brain of severely damaged fetus6 suggests the potential ability of these tissue reservoirs to support both infection and amplification of ZIKV. Furthermore, that the reservoir-derived virus is infectious has been confirmed by sexual- and or transplant-related transmission of infection from non-viremic partners or donors7. These studies raise the possibility that individuals with ZIKV reservoirs could serve as a potential source of endemic and recurrent outbreaks of infection. In addition, the prevalence of such reservoirs in immune compromised patients8 is a major concern as the disease could spread to other organs rapidly and run a more aggressive course, in the absence of immune defenses of the body.
Interestingly, besides tissue reservoirs, few reports have been successful in the detection of ZIKV in the bodily secretions of infected patients, such as saliva9,10 urine9,11, semen and vaginal secretions12–14, breast milk15 and conjunctival fluid16. Semen and vaginal secretions are already reported to be involved in sexual transmission of ZIKV7 in humans. Despite a recent report about the persistence of ZIKV in the semen for more than 6 months17, the duration of the persistence in other bodily secretions (urine, saliva etc) is unclear at this time. Careful evaluation of the duration of the ZIKV shedding and its role in non-sexual transmission needs to be conducted.
Animal models for ZIKV have further confirmed some of these tissue reservoirs18–25. Tang et al. demonstrated the persistence of ZIKV in the vaginal washes as late as 10 days post-infection in lethal and sub-lethal mouse models after intravaginal inoculation of ZIKV26. Ifnar1(-/-) mice showed sustained high viral loads in the brain, spinal cord and testes, confirming these tissue reservoirs21. AG129 mice showed severe pathologies in the muscle and brain27, confirming the presence of these reservoirs in mouse models.
ZIKV was shown to persist in the cerebrospinal fluid (CSF) and lymph nodes (LN) of infected rhesus monkeys weeks after virus clearance from the peripheral blood, urine and mucosal secretions28. Similar observation of longer persistence of ZIKV in the hemolymphatic tissue of non-pregnant rhesus macaques infected with 2015 Brazilian ZIKV isolate was observed by Coffey and colleagues29. ZIKV was also observed in the lacrimal fluid and parotid glands30 of rhesus macaques after subcutaneous infection. ZIKV RNA was detectable in saliva, semen, urine of both rhesus and cynomolgus macaques20. ZIKV infection in the pregnant rhesus macaques showed longer duration of persistence (57 days) compared to normal macaques (21 days)31, suggesting differential persistence depending upon the pregnancy status.
A recent study showed the importance of autophagy on the vertical transmission of ZIKV in pregnant mice32. The authors demonstrated the activity of an autophagy inhibitor approved for use in pregnant women (hydroxychloroquine) in attenuating the placental and fetal ZIKV infection and ameliorated adverse placental and fetal outcomes. Thus animal models could prove useful to study the importance of tissue reservoirs in ZIKV biology and pathogenesis, as well as evaluation of experimental drugs and vaccines.
A review of the literature suggested similar tissue reservoirs observed for other Flaviviruses (Table 2). Tick-borne encephalitis, West Nile Virus and Japanese Encephalitis Virus have varying durations of persistence33. However, unlike other Flaviviruses, sexual transmission is unique to ZIKV infections7. This is not surprising due to ZIKV’s persistence in the genitourinary tract34. The presence of ZIKV in semen is without apparent disease symptoms35, and can be for a period of more than 6 months17. This indicates a need for inclusion of ZIKV in the screening panel for semen donors in addition to the current viruses in the panel (i.e. hepatitis B, C and HIV, as per the guidelines of American Society for Reproductive Medicine and Food and Drug Administration).
Virus | Tissue/Secretion | Duration |
---|---|---|
Siberian Tick Borne encephalitis (TBEV) | Brain/Nervous system | 10 years44 |
Japanese Encephalitis Virus (JEV) | CSF | >3 weeks post- infection45 |
PBMCs | 8–9 months after infection46 | |
West Nile Virus (WNV) | Blood/organ transplants | >40 days47–50 |
Urine | 6.5 years51 |
Another potential concern of ZIKV tissue reservoirs (with low levels of ZIKV) is triggering of sub-neutralizing antibodies leading to antibody-dependent enhancement (ADE) of subsequent Flavivirus infections and potential interplay with other mosquito born Flaviviruses. Recently, ADE of ZIKV by sub-neutralizing Dengue virus antibodies has been reported36,37. Considering the similar target organ affinity (e.g. nervous tissue) observed for other Flaviviruses (e.g. West Nile Virus, Dengue Virus)33, such a concern cannot be ruled out.
The presence of tissue reservoirs and detection of the virus for varying periods of duration, after initial infection, in the absence of the apparent symptoms, poses new challenges for screening of populations. In 2013 during the French Polynesian Zika outbreak, differential virus positivity was observed between the serum, saliva and urine samples collected from 182 patients. Saliva but not serum, from 35 patients was Zika positive. In contrast, serum but not saliva from 16 other patients was Zika positive37. Considering such variability in different biological samples from patients, paired serum and urine samples are considered to be of primary diagnostic importance (CDC guidance for US laboratories testing for Zika virus infections).
Interestingly, in animal studies, low levels of Zika were observed in the body secretions compared to the serum38. Such low levels of ZIKV in the body secretions near the detection limits and invasive processes needed to collect samples (eg. CSF, nervous tissue), suggest currently available detection assays may or may not be suitable to identify persistent ZIKV infections and quantify the tissue reservoirs. As per the CDC information, there are currently no FDA-authorized assays for Zika virus testing of tissue specimens, including fetal and placental tissue, suggesting the need for additional efforts towards such diagnostic assays.
FDA has issued Emergency Use authorization of several diagnostic tools for Zika virus. These include both antibody based and nucleic acid testing (NAT) kits, which are currently distributed to qualified laboratories by the CDC (Table 3).
Antibody based ZIKV detection methods are suggestive of past or recent exposure to Zika and may not necessarily indicate the presence of the virus in the body. In addition, antibody based methods are suitable only for serum, whereas NAT might be suitable for all types of samples including serum and bodily fluids. Due to the direct detection of the virus, NAT-based detection kits might be well suited for the identification of persistent infections. A rapid and high-throughput method for detecting ZIKV RNA using transcription-mediated amplification technology, based Aptima Zika virus assay (Hologic, Marlborough, MA) is described to detect 11.5 to 17.5 genome copy equivalents in serum and urine39. A recent report suggests the utility of isothermal amplification based point-of-care diagnostic technology for rapid detection of ZIKV in the saliva40. The performance of such kits in the clinic remains to be seen. Additional research might shed some light on the acceptable standard for such an effort.
ZIKV tissue reservoirs bring in additional challenges for drug or vaccine development. According to the WHO vaccine pipeline tracker, there are many ZIKV vaccine candidates currently being tested. These include four DNA vaccines (one from GeneOne Life Sciences and three from NIAID), four inactivated whole virus vaccines (3 from NIAID and 1 from BIDMC), one peptide (NIH), one mRNA (Moderna), and one recombinant MV-Zika-101 (Themis Bioscience). Two of these candidates- VRC-ZKADNA090-00-VP (NIAID) and mRNA 1325 (Moderna) are currently recruiting patients for phase 2 trials.
To be effective, potential treatments for ZIKV might have to achieve appropriate tissue concentrations in these reservoirs. This might be limited by sufficient bioavailability of therapeutics in the tissue reservoirs and penetration of the blood brain barrier (BBB). Similar concerns for placental barrier and challenging anatomical locations (e.g. the eyes, kidney, and testes) create additional hurdles for elimination of viral reservoirs. Prophylactic vaccine strategies should be capable of not only preventing infection, but also prevent the establishment of viral reservoirs. In addition, potential vaccine candidates should be capable of inducing a potent neutralizing antibody response to mitigate the possibility of ADE mentioned above.
ZIKV animal models (mice, monkeys) could serve as valuable tools in evaluating the efficacy of therapeutic and prophylactic strategies in eliminating ZIKV tissue reservoirs and prevent shedding of the virus. Additional questions such as relative difference between ZIKV strains to persist in the tissue reservoirs, relative size of different tissue reservoirs (brain, eyes, testes), role of host factors in persistence (tissue reservoir formation), kinetics of virus persistence, and phenotypic and genotypic characterization of the virus in tissue reservoirs, will require additional studies. Formation of ZIKV task force by the Global Virus Networks41 is a welcome move that might be helpful in addressing some of these issues. There is a need for a publically available database (suitable for meta-analysis) to compare long-term kinetics of ZIKV infections and persistence in both animal models and clinical settings. Together with additional research, this might reveal the impact of ZIKV tissue reservoirs on future outbreaks, and drug and vaccine development.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Partly
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Yes
References
1. Musso D, Richard V, Teissier A, Stone M, et al.: Detection of Zika virus RNA in semen of asymptomatic blood donors.Clin Microbiol Infect. 2017. PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Diagnostics and pthogenesis of viral and parasitic infections
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Yes
References
1. Munjal A, Khandia R, Dhama K, Sachan S, et al.: Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives.Front Microbiol. 2017; 8: 1469 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Cellular immunology, Dendritic cell manipulations in Cancer and Infectious Diseases.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 17 Oct 17 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)